Sun Pharmaceutical Industries — Initiation

Thesis: initiating at Underweight

Sun Pharma is an excellent company priced as a story stock. The shares trade at ~34.6x FY27E EPS of ₹54.75 — a premium multiple that assumes the specialty portfolio (Ilumya, Leqselvi, Unloxcyt) and the India business can re-accelerate EPS growth toward the high teens. The reported numbers say otherwise: FY26 EPS grew 4.9% against 11.2% revenue growth, operating margin contracted ~70bps, and free cash flow fell 26% year-over-year. We set a 12-month target of ₹1,500, 27x FY27E EPS — a multiple consistent with ~6–8% earnings growth, implying ~21% downside.

Three things the market may be getting wrong

• The US business is structurally weaker than priced. US formulations grew ~3.6% in FY26 and declined in Q1 FY27; the company has now accepted the White House's Most-Favoured-Nation (MFN) Medicaid pricing regime in exchange for deferred Section 232 tariff exposure — a durable cap on US pricing power across ~28% of revenue.
• The $11.75bn Organon acquisition dilutes quality. Organon generated $6.2bn of declining revenue and only $187m of 2025 net income; the implied acquisition multiple exceeds 60x earnings. A decade of balance-sheet repair (₹289bn net cash) is being spent on a shrinking asset.
• Estimates embed an FY28 catch-up that requires everything to go right. Consensus FY28 EPS of ₹64.53 (+17.9%) needs margin recovery, Organon accretion and no tariff shock simultaneously. The FY27 EPS range across 34 analysts (₹45.50–62.05) is the widest in five years — revision risk is live.

Financial summary (₹ billion, fiscal year ending March)

E = consensus (S&P Global, 34 analysts); A = actual. EPS figures are adjusted. Source: company reports, S&P Global Market Intelligence via stockanalysis.com, Screener.in; independent analysis.

Where we differ from consensus

Consensus (34 analysts) is Buy with an average target of ₹2,167 (+14%); the rating distribution has been deteriorating for six months (Strong Buys down from 23 to 19, Sells doubled to 3) and the lowest published target sits far below the mean. The market prices Sun Pharma as a specialty growth story; the reported P&L — 4.9% EPS growth on 11.2% revenue growth, contracting margins, FCF down 26% — says the specialty ramp is being bought, not earned, and the US base is eroding under MFN pricing.

Risks to our Underweight (where consensus could be right)

• Specialty upside: if Ilumya/Leqselvi/Unloxcyt ramp faster and Organon synergies land early, FY28 EPS could beat the ₹64.5 consensus and re-rate the stock toward its ₹2,000+ street targets.
• MFN relief: any White House exemption or phase-in softer than assumed removes a durable US pricing cap.
• US generics pricing cycle: a normalization of base-US erosion would stabilize ~28% of revenue.

Catalysts

Conclusion

UNDERWEIGHT | PT ₹1,500 (12M) | Conviction: Medium. A 34.6x FY27E multiple on a 5% EPS-grower leaves no margin of safety once the specialty narrative meets the MFN pricing regime and a 60x-priced Organon integration. We would revisit above ₹1,600 only on evidence of US specialty acceleration with stable FCF conversion.

Style exercise prepared for research-format purposes; data as of 7–8 Sep 2026 from company reports, S&P Global Market Intelligence via stockanalysis.com, Screener.in. This document is an AI-generated research note prepared for information and illustration only. It is not investment advice, not an offer to transact, and is not affiliated with or endorsed by any broker or bank. Figures are compiled from third-party public sources that may be delayed or revised. Equity investments carry risk of loss; consult a SEBI-registered investment adviser before acting.

🖨 Print / Save as PDF   ← Back to all research